Literature DB >> 1287224

Cytokines and their role in the pathophysiology of cancer cachexia.

M J McNamara1, H R Alexander, J A Norton.   

Abstract

Cancer cachexia describes a syndrome that consists of weight loss, and abnormalities in carbohydrate, protein, and lipid metabolism, which result in a state of persistent net negative energy balance. Patients suffering from cancer cachexia have a significantly shortened survival after cancer treatment. Recent experimental studies have focused on the belief that the mechanisms of cancer cachexia involve the host's production of inflammatory cytokines, which through broad physiologic actions ultimately lead to a chronic state of wasting, malnourishment, and death. Cytokines that have been thought to play a role in the pathophysiology of cachexia include tumor necrosis factor, interleukin-1, interleukin-6, interferon-gamma and differentiation factor. It has become clear that these cytokines have overlapping physiologic activities, which makes it likely that no single substance is the sole cause of cachexia in most cancer patients. Only further investigation may make it possible to more clearly define the role of cytokines in the pathophysiology of cancer cachexia. Specific strategies to reverse the cachectic effects of these substances may then be developed to ultimately improve cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287224     DOI: 10.1177/014860719201600603

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  21 in total

1.  Cachexia and anorexia.

Authors:  G Mantovani
Journal:  Support Care Cancer       Date:  2000-11       Impact factor: 3.603

Review 2.  Managing cancer-related anorexia/cachexia.

Authors:  G Mantovani; A Macciò; E Massa; C Madeddu
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia.

Authors:  K G Billingsley; D L Fraker; G Strassmann; C Loeser; H M Fliot; H R Alexander
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

Review 4.  Are cytokines possible mediators of cancer cachexia?

Authors:  Y Noguchi; T Yoshikawa; A Matsumoto; G Svaninger; J Gelin
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

5.  Energy expenditure in Japanese patients with severe or moderate ulcerative colitis.

Authors:  Masaya Sasaki; Tomoko Johtatsu; Mika Kurihara; Hiromi Iwakawa; Toshihiro Tanaka; Shigeki Bamba; Tomoyuki Tsujikawa; Yoshihide Fujiyama; Akira Andoh
Journal:  J Clin Biochem Nutr       Date:  2010-04-23       Impact factor: 3.114

6.  Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.

Authors:  G Mantovani; A Macciò; R Versace; M Pisano; P Lai; S Esu; M Ghiani; D Dessì; E Turnu; M C Santona
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

7.  Absence of non-alcoholic fatty liver disease in the presence of insulin resistance is a strong predictor for colorectal carcinoma.

Authors:  Sebahat Basyigit; Metin Uzman; Ayse Kefeli; Ferdane Pirincci Sapmaz; Abdullah Ozgür Yeniova; Yasar Nazligul; Zeliha Asiltürk
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 8.  Pathophysiology of cancer cachexia.

Authors:  U Keller
Journal:  Support Care Cancer       Date:  1993-11       Impact factor: 3.603

9.  Rapid turnover proteins as a prognostic indicator in cancer patients.

Authors:  Y Inoue; R Nezu; H Matsuda; Y Takagi; A Okada
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

10.  Association of interleukin-8 with cachexia from patients with low-third gastric cancer.

Authors:  Bo Song; Dianliang Zhang; Shuchun Wang; Hongmei Zheng; Xinxiang Wang
Journal:  Comp Funct Genomics       Date:  2009-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.